Síguenos en Twitter     Síguenos en Facebook     Síguenos en YouTube     Siguenos en Linkedin     Correo Salutsantjoan     Gmail     Dropbox     Instagram     Google Drive     StumbleUpon     StumbleUpon     StumbleUpon     StumbleUpon     StumbleUpon


My photo
FACP. Colegio de médicos de Tarragona Nº 4305520 / fgcapriles@gmail.com




Friday, March 16, 2018

Endovascular Therapy for Strokes

R.E.B.E.L.EM - March 15, 2018 - By Salim Rezaie
Clinical Take Home Point: 
  • Systemic IV thrombolysis can have limited responsiveness (13 – 50%) to large thrombi in the central circulation, a narrow time window for administration (4.5hrs), and increases the risk of cerebral/systematic hemorrhage
  • The initial 3 trials showing no difference in 90d mRs scores were most likely due to:
    • Proximal occlusion not radiologically proven with intracranial occlusions (i.e. CTA, MRA)
    • The use of first-generation Merci devices as opposed to retrievable stents
    • It is also important to note that in many of the earlier trials there were more new strokes and vessel dissections compared to systemic therapy
  • In the studies reviewed, recruitment averaged about 1 patient per month, meaning this was a very specific and particular patient that was recruited
  • As more and more trials have been performed, the efficiency, the type of imaging, and technology have all also improved, minimizing complications and improving efficacy of endovascular therapy
  • Endovascular therapy for ischemic stroke is suitable for patients with ischemic stroke within 24hrs of symptom onset, with:
    • Proof of proximal intracranial vessel occlusion
    • Imaging methods to exclude large infarct cores
    • Efficient workflow to achieve fast recanalization and high reperfusion rates
    • Workflow: Ischemic Stroke Symptoms ≤24hrs -> CT/CTA -> If CTA positive for large anterior (ICA/MCA) stroke -> CT or MR Perfusion Scan to determine eligibility for Endovascular Therapy
  • Later trials included patients with “wake up” strokes, which have not previously been included in systemic t-PA trials
  • One final note: It is important to realize that many trials were stopped early, and because of this the magnitude of benefit for endovascular therapy may be over inflated in many of these trials